Abigail Brooks, MA

Findings highlight high healthcare resource utilization and costs but low psychotherapy utilization, frequent relapse, and pharmacologic therapy discontinuation.

Saggese explains the importance of second-line therapies in PBC, newly approved treatment options, and their impact on treatment goals and timelines.

Younossi explains how MASH negatively impacts patients’ quality of life and describes resmetirom’s benefit across multiple HRQoL domains.

In addition to the Breakthrough Therapy Designation, Boehringer Ingelheim announced the initiation of 2 phase 3 trials in adults with MASH and fibrosis and compensated MASH cirrhosis.

Findings highlight HCV infection burden among people without injection drug use, a known risk factor for HCV, and call for universal testing to better capture these individuals.

This September 2024 month in review spotlights our top coverage of recent nephrology pipeline updates, guidelines, and research.

Patients taking GLP-1 RAs were more likely to show food retention and inadequate bowel preparation, even when the medications were held before the procedure.

Study findings highlight the individual and combined impact of smoking tobacco and drinking alcohol on achieving PASI75 after 8 weeks of treatment.

The approval is based on findings from BLUE-C, where Cologuard Plus demonstrated sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity.

Contrary to previous research, findings suggest no significant difference in infertility between patients with HS, other dermatological diseases, and healthy controls.

Gross hematuria after COVID-19 mRNA vaccination was more likely in females, patients with IgAN/IgAV, and after the second and third vaccine doses.

This month in review spotlights recent GI pipeline news, new research about IBS and other gastroenterological conditions, and coverage from the 2024 GHAPP conference.

Compared with other international guidelines, the 2024 World Health Organization HBV guidelines had the highest treatment eligibility rates.

Only 6.7% of patients with an abnormal protein dipstick test result had guideline-recommended follow-up albuminuria testing.

This month in review spotlights HCPLive’s coverage of the top hepatic pipeline news and research from September, covering hepatitis, PBC, MASH/MASLD, and more.

The designation was based on positive data from the phase 2b FASCINATE trial of denifanstat in noncirrhotic MASH with moderate to advanced fibrosis.

Bau explains the challenges of using MELD to determine liver transplant referrals and other complexities of the evaluation process.

Positive 120-day data from the phase 2a study of CNP-104 in PBC highlight its efficacy across multiple immunological and clinical measurements

Compared to those without SLD, patients with MASLD, MetALD, and other combination etiology had a greater risk of developing liver and gastrointestinal cancers.

Alcohol intake frequency was linked to a greater risk of IgAN, while dietary exposures like cheese, cereal, and sushi were associated with a reduced risk.

Crimaldi reviews key considerations for the diagnosis and management of bowel ischemia, diverticulitis, and small bowel obstructions in GI inpatients.

HBV education led by healthcare providers, decentralized testing, and strategies with more framework-driven mechanisms had the greatest impact on testing uptake.

Lack of retinopathy, lower hemoglobin A1c levels, preserved eGFR, microalbuminuria, and lower UPCR were linked to non-DKD.

Physicians who received pharmaceutical industry payments related to 4 different direct-acting antivirals were more likely to prescribe these medications.

Leveraging deceased donor kidney transplantation data, study results suggest DCD-V kidney transplantation has similar short- and long-term outcomes versus DCD-III and DBD.

Findings from the prospective cohort study suggest the value of serum Z polymer levels as a non-invasive disease-specific biomarker in patients with homozygous ZZ AATD liver disease.

Magnetic resonance elastography and transient elastography did not accurately predict high-grade fibrosis on liver biopsy in children with MASLD.

Heplisav-B provided a greater vaccine completion rate and higher HBV seroprotection than the conventional 3-dose Recombivax HB in thoracic organ transplant candidates.

Subgroup analyses revealed FMT delivered through endoscopy, nasojejunal tube, and rectal enema had a greater impact on clinical response, symptom improvement, and quality of life.

Meta-analysis findings suggest a significant association between MASLD and serious bacterial infection risk.